HUTCHMED (China) Limited (HCM.L)
HCM.L Stock Price Chart
Explore HUTCHMED (China) Limited interactive price chart. Choose custom timeframes to analyze HCM.L price movements and trends.
HCM.L Company Profile
Discover essential business fundamentals and corporate details for HUTCHMED (China) Limited (HCM.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
19 May 2006
Employees
1.81K
Website
https://www.hutch-med.comCEO
Wei-Guo Su
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
HCM.L Financial Timeline
Browse a chronological timeline of HUTCHMED (China) Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 17 Mar 2026
Upcoming earnings on 29 Jul 2025
Earnings released on 9 May 2025
Earnings released on 19 Mar 2025
EPS came in at £0.01 surpassing the estimated £0.01 by +75.12%, while revenue for the quarter reached £259.39M, beating expectations by +1.65%.
Earnings released on 19 Feb 2025
Earnings released on 31 Jul 2024
EPS came in at £0.01 surpassing the estimated -£0.06 by +118.81%, while revenue for the quarter reached £120.75M, missing expectations by -52.20%.
Earnings released on 10 May 2024
EPS came in at £0.01, while revenue for the quarter reached £121.76M.
Earnings released on 12 Mar 2024
EPS came in at -£0.03 surpassing the estimated -£0.09 by +63.59%, while revenue for the quarter reached £120.73M, missing expectations by -80.06%.
Earnings released on 18 Jan 2024
EPS came in at -£0.03, while revenue for the quarter reached £125.40M.
Earnings released on 31 Jul 2023
EPS came in at £0.08 surpassing the estimated -£0.08 by +195.96%, while revenue for the quarter reached £215.50M, missing expectations by -11.17%.
Earnings released on 30 Jun 2023
EPS came in at £0.08, while revenue for the quarter reached £210.34M.
Earnings released on 28 Feb 2023
EPS came in at -£0.11 surpassing the estimated -£0.20 by +47.73%, while revenue for the quarter reached £101.40M, missing expectations by -79.21%.
Earnings released on 31 Dec 2022
EPS came in at -£0.10, while revenue for the quarter reached £91.45M.
Earnings released on 30 Jun 2022
EPS came in at -£0.08, while revenue for the quarter reached £83.21M.
Earnings released on 31 Mar 2022
EPS came in at -£0.07 surpassing the estimated -£0.17 by +56.41%, while revenue for the quarter reached £76.97M, missing expectations by -46.53%.
Earnings released on 31 Dec 2021
EPS came in at -£0.04, while revenue for the quarter reached £73.67M.
Earnings released on 30 Sept 2021
EPS came in at -£0.04, while revenue for the quarter reached £73.56M.
Earnings released on 30 Jun 2021
EPS came in at -£0.08 falling short of the estimated -£0.05 by -55.82%, while revenue for the quarter reached £54.88M, missing expectations by -16.38%.
Earnings released on 31 Mar 2021
EPS came in at -£0.06, while revenue for the quarter reached £59.01M.
Earnings released on 31 Dec 2020
EPS came in at -£0.04 surpassing the estimated -£0.05 by +24.28%, while revenue for the quarter reached £44.52M, missing expectations by -24.10%.
Earnings released on 30 Sept 2020
EPS came in at -£0.04, while revenue for the quarter reached £46.94M.
HCM.L Stock Performance
Access detailed HCM.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.